371 related articles for article (PubMed ID: 29132352)
1. Intensive care antibiotic consumption and resistance patterns: a cross-correlation analysis.
Baditoiu L; Axente C; Lungeanu D; Muntean D; Horhat F; Moldovan R; Hogea E; Bedreag O; Sandesc D; Licker M
Ann Clin Microbiol Antimicrob; 2017 Nov; 16(1):71. PubMed ID: 29132352
[TBL] [Abstract][Full Text] [Related]
2. Correlation between antimicrobial consumption and antimicrobial resistance of Pseudomonas aeruginosa in a hospital setting: a 10-year study.
Mladenovic-Antic S; Kocic B; Velickovic-Radovanovic R; Dinic M; Petrovic J; Randjelovic G; Mitic R
J Clin Pharm Ther; 2016 Oct; 41(5):532-7. PubMed ID: 27511808
[TBL] [Abstract][Full Text] [Related]
3. Distributed lags time series analysis versus linear correlation analysis (Pearson's r) in identifying the relationship between antipseudomonal antibiotic consumption and the susceptibility of Pseudomonas aeruginosa isolates in a single Intensive Care Unit of a tertiary hospital.
Erdeljić V; Francetić I; Bošnjak Z; Budimir A; Kalenić S; Bielen L; Makar-Aušperger K; Likić R
Int J Antimicrob Agents; 2011 May; 37(5):467-71. PubMed ID: 21277747
[TBL] [Abstract][Full Text] [Related]
4. Clinical characteristics and outcomes of Pseudomonas aeruginosa bacteremia in febrile neutropenic children and adolescents with the impact of antibiotic resistance: a retrospective study.
Kim HS; Park BK; Kim SK; Han SB; Lee JW; Lee DG; Chung NG; Cho B; Jeong DC; Kang JH
BMC Infect Dis; 2017 Jul; 17(1):500. PubMed ID: 28716109
[TBL] [Abstract][Full Text] [Related]
5. [Investigation of the in-vitro effectiveness of ertapenem against Pseudomonas aeruginosa strains isolated from intensive care unit patients].
Kiliç A; Küçükkaraaslan A; Senses Z; Baysallar M; Doğanci L
Mikrobiyol Bul; 2004 Oct; 38(4):355-62. PubMed ID: 15700661
[TBL] [Abstract][Full Text] [Related]
6. Pseudomonas aeruginosa is not just in the intensive care unit any more: implications for empirical therapy.
Eagye KJ; Banevicius MA; Nicolau DP
Crit Care Med; 2012 Apr; 40(4):1329-32. PubMed ID: 22425824
[TBL] [Abstract][Full Text] [Related]
7. Impact of a multimodal strategy combining a new standard of care and restriction of carbapenems, fluoroquinolones and cephalosporins on antibiotic consumption and resistance of Pseudomonas aeruginosa in a French intensive care unit.
Abbara S; Pitsch A; Jochmans S; Hodjat K; Cherrier P; Monchi M; Vinsonneau C; Diamantis S
Int J Antimicrob Agents; 2019 Apr; 53(4):416-422. PubMed ID: 30537533
[TBL] [Abstract][Full Text] [Related]
8. Resistance patterns of Pseudomonas aeruginosa to carbapenems and piperacillin/tazobactam.
Mokaddas EM; Sanyal SC
J Chemother; 1999 Apr; 11(2):93-6. PubMed ID: 10326738
[TBL] [Abstract][Full Text] [Related]
9. Correlation between meropenem and doripenem use density and the incidence of carbapenem-resistant Pseudomonas aeruginosa.
Shigemi A; Matsumoto K; Yaji K; Shimodozono Y; Takeda Y; Miyanohara H; Kawamura H; Orita M; Tokuda K; Nishi J; Yamada K
Int J Antimicrob Agents; 2009 Dec; 34(6):589-91. PubMed ID: 19748231
[TBL] [Abstract][Full Text] [Related]
10. Characteristics of carbapenem-resistant Pseudomonas aeruginosa strains in patients with ventilator-associated pneumonia in intensive care units.
Vitkauskienė A; Skrodenienė E; Dambrauskienė A; Bakšytė G; Macas A; Sakalauskas R
Medicina (Kaunas); 2011; 47(12):652-6. PubMed ID: 22370463
[TBL] [Abstract][Full Text] [Related]
11. Antimicrobial Susceptibility of Enterobacteriaceae and Pseudomonas aeruginosa Isolates from United States Medical Centers Stratified by Infection Type: Results from the International Network for Optimal Resistance Monitoring (INFORM) Surveillance Program, 2015-2016.
Sader HS; Castanheira M; Duncan LR; Flamm RK
Diagn Microbiol Infect Dis; 2018 Sep; 92(1):69-74. PubMed ID: 29789189
[TBL] [Abstract][Full Text] [Related]
12. Risk of emergence of Pseudomonas aeruginosa resistance to beta-lactam antibiotics in intensive care units.
Georges B; Conil JM; Dubouix A; Archambaud M; Bonnet E; Saivin S; Lauwers-Cancès V; Cristini C; Cougot P; Decun JF; Mathe O; Chabanon G; Marty N; Seguin T; Houin G
Crit Care Med; 2006 Jun; 34(6):1636-41. PubMed ID: 16557152
[TBL] [Abstract][Full Text] [Related]
13. Impact of carbapenem restriction on the antimicrobial susceptibility pattern of Pseudomonas aeruginosa isolates in the ICU.
Abdallah M; Badawi M; Amirah MF; Rasheed A; Mady AF; Alodat M; Alharthy A
J Antimicrob Chemother; 2017 Nov; 72(11):3187-3190. PubMed ID: 28961733
[TBL] [Abstract][Full Text] [Related]
14. The effects of group 1 versus group 2 carbapenems on imipenem-resistant Pseudomonas aeruginosa: an ecological study.
Carmeli Y; Lidji SK; Shabtai E; Navon-Venezia S; Schwaber MJ
Diagn Microbiol Infect Dis; 2011 Jul; 70(3):367-72. PubMed ID: 21683268
[TBL] [Abstract][Full Text] [Related]
15. Antimicrobial resistance patterns of Pseudomonas aeruginosa in tertiary care hospitals of Makkah and Jeddah.
Khan MA; Faiz A
Ann Saudi Med; 2016; 36(1):23-8. PubMed ID: 26922684
[TBL] [Abstract][Full Text] [Related]
16. Anti-pseudomonal beta-lactams for the initial, empirical, treatment of febrile neutropenia: comparison of beta-lactams.
Paul M; Yahav D; Bivas A; Fraser A; Leibovici L
Cochrane Database Syst Rev; 2010 Nov; 2010(11):CD005197. PubMed ID: 21069685
[TBL] [Abstract][Full Text] [Related]
17. A new carbapenem drug dosage metric for carbapenem usage and correlation with carbapenem resistance of Pseudomonas aeruginosa.
Hirayama S; Yasui K; Murakami H; Kosugi T; Sakamoto M; Hanai Y; Matsuo K; Miyazaki T; Ishii Y; Nishizawa K; Tateda K
J Infect Chemother; 2018 Dec; 24(12):949-953. PubMed ID: 30268412
[TBL] [Abstract][Full Text] [Related]
18. Changes in the use of broad-spectrum antibiotics after cefepime shortage: a time series analysis.
Plüss-Suard C; Pannatier A; Ruffieux C; Kronenberg A; Mühlemann K; Zanetti G
Antimicrob Agents Chemother; 2012 Feb; 56(2):989-94. PubMed ID: 22123703
[TBL] [Abstract][Full Text] [Related]
19. Relationship between the usage of carbapenem antibiotics and the incidence of imipenem-resistant Pseudomonas aeruginosa.
Fujimura S; Nakano Y; Sato T; Shirahata K; Watanabe A
J Infect Chemother; 2007 Jun; 13(3):147-50. PubMed ID: 17593500
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of combination therapy with cefepime, piperacillin-tazobactam, or meropenem with ciprofloxacin against multidrug-resistant Pseudomonas aeruginosa strains.
Erdem I; Kucukercan M; Ceran N
Chemotherapy; 2003 Dec; 49(6):294-7. PubMed ID: 14671429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
